Skip to main content
Premium Trial:

Request an Annual Quote

Wageningen University Bodies Form Animal-Based Functional-Genomics Partnership

NEW YORK, March 5 - Greenomics, the sequencing arm of the Plant Research International, and ID-Lelystad, an international research firm, on Tuesday said they hope to use functional genomics and bioinformatics technology to improve veterinary breeding and develop vaccines.

The agreement, which will initially run for two years, seeks to correlate genotypic and phenotypic data, according to RJM Moormann, the manager of business development at ID-Lelystad.


Greenomics, considered the largest facility for DNA sequencing in the Netherlands, will grant access to its large-scale genome sequencing facilities, while IL-Lelystad will provide it experience in veterinary biology.

Though financial terms of the agreement were not disclosed, Moormann said that any marketable data generated by the collaboration will be commercialized. He estimates that "one good vaccine product" can generate between $50 million and $100 million worldwide.

ID-Lelystad and Plant Research International are part of Wageningen University and Research Centre, based in Wageningen, the Netherlands. ID-Lelystad is an international contract research organization that focuses on applied research in animal health, welfare and stress, animal feed, genetics and biomedical research, and food safety.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.